Curia

Articles

Webcasts

FDA's Quality Management Maturity Program: Why Should CDMOs Adhere to the New CDER's Rating System?

Webinar Date/Time: Wed, Sep 27, 2023 11:00 AM EDT

Webcasts

A customized approach to mRNA manufacturing

Webinar Date/Time: Wed, May 10, 2023 11:00 AM EDT

Advances in the Antibody Drug Development Workflow

Partnering with a single CDMO can increase speed to market, ensure production capacity and avoid costly-time consuming tech transfers. Learn more inside this eBook.

The current and future value of mRNA vaccines and therapeutics

The value of engaging a single CDMO for comprehensive biologics services from discovery to GMP manufacturing

Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

Shift Toward US Pharmaceutical Manufacturing

Leveraging efficiency from cell line development to clinical manufacturing of monoclonal antibodies

Antibody-based drug discovery at the speed of light

Sponsored Content

The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.

Sponsored Content

Curia's CHO-GSN™ Platform

Curia's CHO-GSN™ platform is a stable cell line development service maximizing purity and yield.